首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   894篇
  免费   51篇
  国内免费   70篇
耳鼻咽喉   10篇
儿科学   26篇
妇产科学   8篇
基础医学   144篇
口腔科学   4篇
临床医学   151篇
内科学   187篇
皮肤病学   8篇
神经病学   44篇
特种医学   70篇
外科学   75篇
综合类   23篇
预防医学   73篇
眼科学   15篇
药学   98篇
中国医学   13篇
肿瘤学   66篇
  2023年   8篇
  2022年   32篇
  2021年   61篇
  2020年   27篇
  2019年   29篇
  2018年   28篇
  2017年   15篇
  2016年   13篇
  2015年   18篇
  2014年   32篇
  2013年   42篇
  2012年   50篇
  2011年   52篇
  2010年   37篇
  2009年   27篇
  2008年   35篇
  2007年   83篇
  2006年   41篇
  2005年   44篇
  2004年   24篇
  2003年   33篇
  2002年   32篇
  2001年   14篇
  2000年   16篇
  1999年   14篇
  1998年   25篇
  1997年   21篇
  1996年   21篇
  1995年   15篇
  1994年   8篇
  1993年   8篇
  1992年   3篇
  1991年   10篇
  1990年   7篇
  1989年   16篇
  1988年   12篇
  1987年   11篇
  1986年   9篇
  1985年   4篇
  1984年   6篇
  1983年   6篇
  1982年   2篇
  1981年   2篇
  1980年   3篇
  1978年   2篇
  1977年   6篇
  1976年   3篇
  1975年   3篇
  1974年   1篇
  1973年   3篇
排序方式: 共有1015条查询结果,搜索用时 93 毫秒
11.
BACKGROUND: In anovulatory women undergoing ovulation induction, addition of recombinant human LH (rLH) to FSH treatment may promote the dominance of a leading follicle when administered in the late follicular phase. The objective of this study was to find the optimal dose of rLH that can maintain the growth of a dominant follicle, whilst causing atresia of secondary follicles. METHODS: Women with infertility due to anovulation and over-responding to FSH treatment were randomized to receive, in addition to 37.5 IU recombinant human FSH (rFSH), either placebo or different doses of rLH (6.8, 13.6, 30 or 60 microg) daily for a maximum of 7 days. The primary efficacy endpoint was the proportion of patients who had exactly one follicle > or = 16 mm on hCG day. RESULTS: Among 153 enrolled patients, the five treatment groups were similar in terms of baseline characteristics. The proportion of patients with exactly one follicle > or = 16 mm ranged from 13.3% in the placebo group to 32.1% in the 30 microg rLH group (P = 0.048). The pregnancy rate ranged from 10.3% in the 60 microg group to 28.6% in the 30 microg rLH group. Adverse events were similar between groups. CONCLUSIONS: In patients over-responding to FSH during ovulation induction, doses of up to 30 microg rLH/day appear to increase the proportion of patients developing a single dominant follicle (> or = 16 mm). Our data support the 'LH ceiling' concept whereby addition of rLH is able to control development of the follicular cohort.  相似文献   
12.
The personality of patients suffering from Parkinson's disease has been considered as the basis of a psychosomatic theory or more simply as a form of reaction. Between these two extremes the controversy continues and is modified by the use of dopaminergic agents. In this study, 30 patients suffering from parkinson's disease undergo a psychological examination and a M.M.P.I.; the results allow us to determine a pre-morbid obsessive personality coupled with agressivity and ambition. A transformation occurs with the arrival of illness; dependence, passivity, suggestibility evolve in a context where anxiety is relieved of all agressivity but acquires a depressive character. The people surrounding the patients play a part in this transformation. Moreover the pre-morbid characteristics of these patients remind the physician of H. Tellenbach's "typus melancholicus".  相似文献   
13.
In two headache questionnaire surveys we inquired about the occurrence of headache in the mothers, fathers, siblings and children of the respondents. In total, 633 people completed valid questionnaires, 260 in the first survey and 373 in the second. The hypothesis was that familial headache occurrence would be positively associated with headache frequency. In each survey, the regression of headache frequency on the number of parents having headache was highly significant. Neither sex nor the sibling and children variables were significant predictors. In the cross-tabulations of the parental occurrence of headache with headache frequency we saw a clear "break-point" between the "no headache" and the headache frequency categories studied. For the final analyses the dichotomy "headache/no headache" was related in fourfold tables to headache occurrence in the father and the mother separately, and to the number of headache parents. The positive associations were not simply due to the large number of migraine cases since they remained after removing the migraineurs.  相似文献   
14.
OBJECTIVE: To evaluate radiotherapy dose and length of treatment in the control of early stage nasopharyngeal carcinoma (NPC) treated with a combination of external radiotherapy and brachytherapy, MATERIALS & METHODS: We reviewed the records of 133 patients with early stage nasopharyngeal carcinoma (stage I or II, AJC/UICC staging system) who received definitive radiotherapy in Chang Gung Memorial Hospital from 1979 to 1991. The median follow-up time was 7.1 years with a minimum of 2 years. All patients were treated with megavoltage external radiotherapy to the nasopharynx area (63-72 Gy) followed by high dose rate intracavitary brachytherapy (5-16.5 Gy in one to three fractions, spaced 1-2 weeks apart). The median total dose and time of irradiation was 75 Gy (69.8-81.4 Gy) and 11.6 weeks (7.8-20 weeks) respectively. Survival analysis was used to examine the effect of several variables on prognosis. RESULTS: The 5-year rates were 86.4% for local control, 84.7% for disease free survival, 88.5% for actuarial survival and 84.2% for overall survival. The treatment group (combination of time and dose of irradiation) was the most important prognostic factor according to Cox's proportional hazard model. Patients receiving radiation at a total dose of < or = 75 Gy completed in < 12 weeks showed the best prognosis. CONCLUSION: Treatment time and total treatment dose are both important factors in treating early stage NPC. Decreasing the total radiation time to < 12 weeks and not exceeding a radiation dose of 75 Gy gave the best results.   相似文献   
15.
16.
17.
18.
19.
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号